Abstract
Background Depressive and neurocognitive disorders are debilitating conditions that account for the leading causes of years lived with disability worldwide. Overcoming these disorders is an extremely important public health problem today. However, there are no biomarkers that are objective or easy-to-obtain in daily clinical practice, which leads to difficulties in assessing treatment response and developing new drugs. Due to advances in technology, it has become possible to quantify important features that clinicians perceive as reflective of disorder severity. Such features include facial expressions, phonic/speech information, body motion, daily activity, and sleep. The overall goal of this proposed study, the Project for Objective Measures Using Computational Psychiatry Technology (PROMPT), is to develop objective, noninvasive, and easy-to-use biomarkers for assessing the severity of depressive and neurocognitive disorders.
Methods This is a multi-center prospective study. DSM-5 criteria for major depressive disorder, bipolar disorder, and major and minor neurocognitive disorders are inclusion criteria for the depressive and neurocognitive disorder samples. Healthy samples are confirmed to have no history of psychiatric disorders by Mini-International Neuropsychiatric Interview, and have no current cognitive decline based on the Mini Mental State Examination. Participants go through approximately 10-minute interviews with a psychiatrist/psychologist, where participants talk about non-specific topics such as everyday living, symptoms of disease, hobbies, etc. Interviews are recorded using RGB and infrared cameras, and an array microphone. As an option, participants are asked to wear wrist-band type devices during the observational period. The interviews take place ≤10 times within up to five years of follow-up. Various software is used to process the raw video, voice, infrared, and wearable device data. A machine learning approach is used to predict the presence of symptoms, severity, and the improvement/deterioration of symptoms.
Discussion The PROMPT goal is to develop objective digital biomarkers for assessing the severity of depressive and neurocognitive disorders in the hopes of guiding decision-making in clinical settings as well as reducing the risk of clinical trial failure. Challenges may include the large variability of samples, which makes it difficult to extract the features that commonly reflect disorder severity.
Trial Registration UMIN000021396, University Hospital Medical Information Network (UMIN)
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; T. Kishimoto reports personal fees from Otsuka, Pfizer, and Dainippon Sumitomo, Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer; KF reports personal fees from Novartis and Mochida, non-financial support from Otsuka; HT is an employee of FRONTEO; TH reports personal fees from Yoishitomi; T. Kikuchi has reports personal fees from Astellas, Dainippon Sumitomo, Eli Lilly, Janssen, MSD, Otsuka, Yoshitomi Yakuhin, Pfizer, and Takeda; JM reports personal fees from Eli Lilly, Janssen, Otsuka, MSD, Shionogi, and Pfizer; MM reports personal fees from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin, and he received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi, and Tsumura. Other authors have no conflict of interest; no other relationships or activities that could appear to have influenced the submitted work.
Clinical Trial
UMIN000021396
Clinical Protocols
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000024677
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000027146
Funding Statement
This research is supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP18he1102004. The Grant was awarded on Oct. 29, 2015 and ends on Mar. 31, 2019. The funding source did not participate in the design of this study and will not have any hand in the study’s execution, analyses, or submission of results. Japan Agency for Medical Research and Development (AMED) 20F Yomiuri Shimbun Bldg. 1-7-1 Otemachi, Chiyoda-ku, Tokyo 100-0004 Japan Tel: +81-3-6870-2200, Fax: +81-3-6870-2241, Email: jimu-ask@amed.go.jp
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not applicable.
Abbreviations
- UMIN
- University Hospital Medical Information Network
- UI
- uncertainty interval
- YLDs
- years lived with disability
- HAM-D
- Hamilton Depression Rating Scale
- MADRS
- Montgomery-Asberg Depression Rating Scale
- PET
- positron emission tomography
- MRI
- magnetic resonance imaging
- MCI
- mild cognitive impairment
- MMSE
- Mini-Mental State Examination
- MoCA
- Montreal Cognitive Assessment
- PROMPT
- Project for Objective Measures Using Computational Psychiatry Technology
- AMED
- Japan Agency for Medical Research and Development
- DSM-5
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
- SCID
- Structural Clinical Interview for DSM-5
- M.I.N.I.
- Mini-International Neuropsychiatric Interview
- RGB
- red, green, blue
- UV
- ultraviolet
- ISO
- International Organization for Standardization
- FedRAMP
- Federal Risk and Authorization Management Program
- IEC
- International Electrotechnical Commission
- BDI-II
- Beck Depression Inventory, Second Edition
- F0
- fundamental frequency
- F1, F2, F3
- first, second, and third formant frequencies
- CPP
- cepstral peak prominence
- MFCC
- mel-frequency cepstrum coefficients
- SVR
- Support Vector Regression
- SVM
- Support Vector Machine
- RF
- Random Forest
- Adaboost
- Adaptive Boosting
- Adabag
- Adaptive Bagging
- CNN
- Convolutional Neural Networks
- GCN
- Gated Convolutional Neural Networks
- BNN
- Bayesian Neural Networks
- LSTM
- Long Short-Term Memory Networks
- MARS
- Motor Agitation and Retardation Scale
- MDD
- Major depressive disorder
- BD
- Bipolar disorder
- YMRS
- Young Mania Rating Scale
- PSQI
- Pittsburgh Sleep Quality Index
- CDR
- Clinical Dementia Rating
- LM
- Wechsler Memory Scale-Revised Logical Memory
- CDT
- Clock Drawing Test
- NPI
- Neuropsychiatric Inventory
- GDS
- Geriatric Depression Scale
